Similarly, a phase-II clinical study showed that granulocyte-macrophage colony-stimulating factor therapy decreased antibiotics treatment time and infectious complications but didn’t improve the in-hospital mortality rate of sepsis patients (Presneill et al., 2002). This evidence concerns the gene CSF2 and Sepsis.